β-adrenoceptor blockers and serotonin

Serotonin-2-receptor Blockers and Preeclampsia

Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers.

AIMS Obesity can modify the pharmacokinetics of lipophilic drugs. As beta-adrenoceptor blockers (BB) are often prescribed for obese patients suffering from hypertension or coronary heart disease, this study compares the pharmacokinetics of lipophilic beta-adrenoceptor blockers in obese and control subjects. METHODS Nine obese (157 +/- 24% of ideal body weight (IBW) mean +/- s.d.) and nine non...

β-blockers for COPD inpatients.

For clinicians who treat patients with respiratory diseases, the use of β-blockers has, for a long time, posed a dilemma because of the potential risk of bronchospasm and neutralisation of the effectiveness of β-2 agonists. This predicament is particularly challenging for patients with chronic obstructive pulmonary disease (COPD), many of whom have substantial cardiovascular comorbidity, and in...

Hemangiomas and β-Blockers: On the Rebound.

Infantile hemangioma (IH) is the most common tumor of childhood, and although most lesions eventually involute, the proliferative phase may be associated with complications, such as ulceration, bleeding, functional compromise, and anatomic disfigurement. Rarely, IH can have major or life-threatening consequences, such as airway obstruction, high-output congestive heart failure, and consumptive ...

β blockers in hypertension and cardiovascular disease

β blockers are useful in managing angina and reducing mortality after myocardial infarction and in heart failure. They probably reduce cardiovascular events in high risk surgery and retard the progression of atherosclerosis. In younger patients, β blockers should remain first line antihypertensives, together with diuretics, calcium channel blockers, angiotensin converting enzymes, and adrenergi...